Concord Biotech Secures USFDA Approval for Mycophenolate Mofetil Oral Suspension
Concord Biotech Ltd has announced that it has received approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) covering Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL.Mycophenolate mofetil is categorized as an antimetabolite immunosuppressant. It is indicated for the prophylaxis of organ rejection in adult and pediatric recipients aged 3 months and older following allogeneic kidney, heart, or liver transplants, used in combination with other immunosuppressants.The approval is significant for the company's growth trajectory in the U.S. and international sectors. According to market estimates...